Importance of IL-10 and IL-6 during chronic hepatitis c genotype-1 treatment and their relation with IL28B

Cytokine

Volumn 61, Issue 2, 2013, Pages 595-601

  Pavón Castillero, Esther J ^a   Muñoz de Rueda, Paloma ^a,b   López Segura, Rosario ^a   Gila, Ana ^a,b   Quiles, Rosa ^a,b   Muñoz Gámez, Jose A ^a   Carazo, Ángel ^a   Martínez, Pilar ^a   Ruiz Extremera, Ángeles ^a,b,c   Salmerón, Javier ^a,b,c  

^a HOSPITAL UNIVERSITARIO SAN CECILIO   (Spain)

^b INSTITUTO DE SALUD CARLOS III   (Spain)

^c UNIVERSITY OF GRANADA   (Spain)

Author keywords

Chronic hepatitis C genotype 1; Cytokines; PegIFN RBV; Polymorphisms; Sustained virological response

Indexed keywords

GAMMA GLUTAMYLTRANSFERASE; INTERLEUKIN 10; INTERLEUKIN 28B; INTERLEUKIN 6; PEGINTERFERON ALPHA2A; RIBAVIRIN;

ADULT; AGE; ARTICLE; COHORT ANALYSIS; CONTROLLED STUDY; ENZYME ACTIVITY; FEMALE; GENETIC ASSOCIATION; GENETIC POLYMORPHISM; GENOTYPE; GENOTYPE PHENOTYPE CORRELATION; HEPATITIS C; HUMAN; IMMUNOASSAY; MAJOR CLINICAL STUDY; MALE; MULTIVARIATE LOGISTIC REGRESSION ANALYSIS; PREDICTION; PRIORITY JOURNAL; PROTEIN EXPRESSION; RETROSPECTIVE STUDY; STATISTICAL SIGNIFICANCE; TREATMENT DURATION; TREATMENT OUTCOME; TREATMENT RESPONSE; VIRUS LOAD;

ADULT; FEMALE; GENETIC ASSOCIATION STUDIES; GENOTYPE; HEPATITIS C, CHRONIC; HUMANS; INTERLEUKIN-10; INTERLEUKIN-6; INTERLEUKINS; MALE; PHENOTYPE;

HEPATITIS C VIRUS;

EID: 84873138833     PISSN: 10434666     EISSN: 10960023     Source Type: Journal    
DOI: 10.1016/j.cyto.2012.10.009     Document Type: Article

References (31)

1. Seeff L.B. Natural history of chronic hepatitis C. Hepatology 2002, 36:S35-S46.
2. Cramp M.E., Carucci P., Rossol S., Chokshi S., Maertens G., Williams R., et al. Hepatitis C virus (HCV) specific immune responses in anti-HCV positive patients without hepatitis C viraemia. Gut 1999, 44:424-429.
3. Pape G.R., Gerlach T.J., Diepolder H.M., Gruner N., Jung M., Santantonio T. Role of the specific T-cell response for clearance and control of hepatitis C virus. J Viral Hepat 1999, 6(Suppl 1):36-40.
4. Trapero-Marugan M., Garcia-Buey L., Munoz C., Quintana N.E., Moreno-Monteagudo J.A., Borque M.J., et al. Sustained virological response to peginterferon plus ribavirin in chronic hepatitis C genotype 1 patients is associated with a persistent Th1 immune response. Aliment Pharmacol Ther 2006, 24:117-128.
5. Ollier W.E. Cytokine genes and disease susceptibility. Cytokine 2004, 28:174-178.
6. Moore K.W., de Waal Malefyt R., Coffman R.L., O'Garra A. Interleukin-10 and the interleukin-10 receptor. Annu Rev Immunol 2001, 19:683-765.
7. Taga T., Kishimoto T. Gp130 and the interleukin-6 family of cytokines. Annu Rev Immunol 1997, 15:797-819.
8. Yoneda S., Umemura T., Katsuyama Y., Kamijo A., Joshita S., Komatsu M., et al. Association of serum cytokine levels with treatment response to pegylated interferon and ribavirin therapy in genotype 1 chronic hepatitis C patients. J Infect Dis 2011, 203:1087-1095.
9. Cussigh A., Falleti E., Fabris C., Bitetto D., Cmet S., Fontanini E., et al. Interleukin 6 promoter polymorphisms influence the outcome of chronic hepatitis C. Immunogenetics 2011, 63:33-41.
10. Zhang L.Z., Zhang T.C., Pan F.M., Zhang Z.H., Li X. Interleukin-10 gene polymorphisms in association with susceptibility to chronic hepatitis C virus infection: a meta-analysis study. Arch Virol 2010, 155:1839-1842.
11. Ge D., Fellay J., Thompson A.J., Simon J.S., Shianna K.V., Urban T.J., et al. Genetic variation in IL28B predicts hepatitis C treatment-induced viral clearance. Nature 2009, 461:399-401.
12. Thomas D.L., Thio C.L., Martin M.P., Qi Y., Ge D., O'Huigin C., et al. Genetic variation in IL28B and spontaneous clearance of hepatitis C virus. Nature 2009, 461:798-801.
13. Lin C.Y., Chen J.Y., Lin T.N., Jeng W.J., Huang C.H., Huang C.W., et al. IL28B SNP rs12979860 is a critical predictor for on-treatment and sustained virologic response in patients with hepatitis C virus genotype-1 infection. PLoS One 2011, 6:e18322.
14. Sheppard P., Kindsvogel W., Xu W., Henderson K., Schlutsmeyer S., Whitmore T.E., et al. IL-28, IL-29 and their class II cytokine receptor IL-28R. Nat Immunol 2003, 4:63-68.
15. de Rueda P.M., Lopez-Nevot M.A., Saenz-Lopez P., Casado J., Martin-Casares A., Palomares P., et al. Importance of host genetic factors HLA and IL28B as predictors of response to pegylated interferon and ribavirin. Am J Gastroenterol 2011, 106:1246-1254.
16. Caballero T., Perez-Milena A., Masseroli M., O'Valle F., Salmeron F.J., Del Moral R.M., et al. Liver fibrosis assessment with semiquantitative indexes and image analysis quantification in sustained-responder and non-responder interferon-treated patients with chronic hepatitis C. J Hepatol 2001, 34:740-747.
17. Mauss S., Hueppe D., John C., Goelz J., Heyne R., Moeller B., et al. Estimating the likelihood of sustained virological response in chronic hepatitis C therapy. J Viral Hepat 2011, 18:e81-e90.
18. Villela-Nogueira C.A., Perez R.M., de Segadas Soares J.A., Coelho H.S. Gamma-glutamyl transferase (GGT) as an independent predictive factor of sustained virologic response in patients with hepatitis C treated with interferon-alpha and ribavirin. J Clin Gastroenterol 2005, 39:728-730.
19. Costa J.M., Telehin D., Munteanu M., Kobryn T., Ngo Y., Thibault V., et al. HCV-Genofibrotest: a combination of viral, liver and genomic (IL28B, ITPA, UGT1A1) biomarkers for predicting treatment response in patients with chronic hepatitis C. Clin Res Hepatol Gastroenterol 2011.
20. Streetz K.L., Tacke F., Leifeld L., Wustefeld T., Graw A., Klein C., et al. Interleukin 6/gp130-dependent pathways are protective during chronic liver diseases. Hepatology 2003, 38:218-229.
21. Colakogullari M., Ulukaya E., Yilmaztepe Oral A., Aymak F., Basturk B., Ursavas A., et al. The involvement of IL-10, IL-6, IFN-gamma, TNF-alpha and TGF-beta gene polymorphisms among turkish lung cancer patients. Cell Biochem Funct 2008, 26:283-290.
22. Ziegler-Heitbrock L., Lotzerich M., Schaefer A., Werner T., Frankenberger M., Benkhart E. IFN-alpha induces the human IL-10 gene by recruiting both IFN regulatory factor 1 and stat3. J Immunol 2003, 171:285-290.
23. Aman M.J., Tretter T., Eisenbeis I., Bug G., Decker T., Aulitzky W.E., et al. Interferon-alpha stimulates production of interleukin-10 in activated CD4+ T cells and monocytes. Blood 1996, 87:4731-4736.
24. Wan L., Kung Y.J., Lin Y.J., Liao C.C., Sheu J.J., Tsai Y., et al. Th1 and Th2 cytokines are elevated in HCV-infected SVR(-) patients treated with interferon-alpha. Biochem Biophys Res Commun 2009, 379:855-860.
25. Torre F., Rossol S., Pelli N., Basso M., Delfino A., Picciotto A. Kinetics of soluble tumour necrosis factor (TNF)-alpha receptors and cytokines in the early phase of treatment for chronic hepatitis C: comparison between interferon (IFN)-alpha alone, IFN-alpha plus amantadine or plus ribavirin. Clin Exp Immunol 2004, 136:507-512.
26. Tsai S.L., Liaw Y.F., Chen M.H., Huang C.Y., Kuo G.C. Detection of type 2-like T-helper cells in hepatitis C virus infection: implications for hepatitis C virus chronicity. Hepatology 1997, 25:449-458.
27. Cacciarelli T.V., Martinez O.M., Gish R.G., Villanueva J.C., Krams S.M. Immunoregulatory cytokines in chronic hepatitis C virus infection: pre- and posttreatment with interferon alfa. Hepatology 1996, 24:6-9.
28. Brooks D.G., Trifilo M.J., Edelmann K.H., Teyton L., McGavern D.B., Oldstone M.B. Interleukin-10 determines viral clearance or persistence in vivo. Nat Med 2006, 12:1301-1309.
29. Diaz-Valdes N., Manterola L., Belsue V., Riezu-Boj J.I., Larrea E., Echeverria I., et al. Improved dendritic cell-based immunization against hepatitis C virus using peptide inhibitors of interleukin 10. Hepatology 2011, 53:23-31.
30. Commins S., Steinke J.W., Borish L. The extended IL-10 superfamily: IL-10, IL-19, IL-20, IL-22, IL-24, IL-26, IL-28, and IL-29. J Allergy Clin Immunol 2008, 121:1108-1111.
31. Uze G., Monneron D. IL-28 and IL-29: newcomers to the interferon family. Biochimie 2007, 89:729-734.